These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 2436197

  • 1. Comparison of responses by striatonigral substance P and neurokinin A systems to methamphetamine treatment.
    Hanson GR, Letter AA, Merchant K, Gibb JW.
    Peptides; 1986; 7(6):983-7. PubMed ID: 2436197
    [Abstract] [Full Text] [Related]

  • 2. Response of extrapyramidal and limbic neuropeptides to fenfluramine administration: comparison with methamphetamine.
    Hanson GR, Singh N, Bush L, Gibb JW.
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1197-202. PubMed ID: 1722253
    [Abstract] [Full Text] [Related]

  • 3. Characterization of methamphetamine effects on the striatal-nigral dynorphin system.
    Hanson GR, Merchant KM, Letter AA, Bush L, Gibb JW.
    Eur J Pharmacol; 1988 Oct 11; 155(1-2):11-8. PubMed ID: 2907484
    [Abstract] [Full Text] [Related]

  • 4. Dopamine-mediated increases in nigral substance P-like immunoreactivity.
    Ritter JK, Schmidt CJ, Gibb JW, Hanson GR.
    Biochem Pharmacol; 1985 Sep 01; 34(17):3161-6. PubMed ID: 2412564
    [Abstract] [Full Text] [Related]

  • 5. Effects of GABA and L-glutamic acid on the potassium-evoked in vitro release of substance P- and neurokinin A-like immunoreactivities are different in the rat striatum and substantia nigra.
    Humpel C, Saria A.
    Neurosci Lett; 1989 Oct 23; 105(1-2):159-63. PubMed ID: 2484728
    [Abstract] [Full Text] [Related]

  • 6. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
    Lindefors N, Brodin E, Tossman U, Segovia J, Ungerstedt U.
    Exp Brain Res; 1989 Oct 23; 74(3):527-34. PubMed ID: 2468514
    [Abstract] [Full Text] [Related]

  • 7. Effects of BDNF and NT-4/5 on striatonigral neuropeptides or nigral GABA neurons in vivo.
    Arenas E, Akerud P, Wong V, Boylan C, Persson H, Lindsay RM, Altar CA.
    Eur J Neurosci; 1996 Aug 23; 8(8):1707-17. PubMed ID: 8921261
    [Abstract] [Full Text] [Related]

  • 8. Ascorbic acid-deficient condition alters central effects of methamphetamine.
    Matsuda LA, Schmidt CJ, Gibb JW, Hanson GR.
    Brain Res; 1987 Jan 01; 400(1):176-80. PubMed ID: 2434185
    [Abstract] [Full Text] [Related]

  • 9. Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation.
    Sonsalla PK, Gibb JW, Hanson GR.
    Eur J Pharmacol; 1984 Oct 01; 105(1-2):185-7. PubMed ID: 6208043
    [Abstract] [Full Text] [Related]

  • 10. Blockade of tachykinin NK1 receptors by CP-96345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats.
    Gygi SP, Gibb JW, Johnson M, Hanson GR.
    Eur J Pharmacol; 1993 Nov 30; 250(1):177-80. PubMed ID: 7509751
    [Abstract] [Full Text] [Related]

  • 11. Evidence that neurokinin A (substance K) neurons project from the striatum to the substantia nigra in rats.
    Nagashima A, Takano Y, Masui H, Kamiya H.
    Neurosci Lett; 1987 Jun 01; 77(1):103-8. PubMed ID: 3037449
    [Abstract] [Full Text] [Related]

  • 12. Neurokinin A and substance P in striato-nigral neurons in rat brain.
    Lindefors N, Brodin E, Ungerstedt U.
    Neuropeptides; 1986 Jun 01; 8(2):127-32. PubMed ID: 2429229
    [Abstract] [Full Text] [Related]

  • 13. Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine.
    Hanson GR, Bush L, Keefe KA, Alburges ME.
    J Neurochem; 2002 Sep 01; 82(5):1171-8. PubMed ID: 12358764
    [Abstract] [Full Text] [Related]

  • 14. Effect of methamphetamine on neurotensin concentrations in rat brain regions.
    Letter AA, Merchant K, Gibb JW, Hanson GR.
    J Pharmacol Exp Ther; 1987 May 01; 241(2):443-7. PubMed ID: 3572804
    [Abstract] [Full Text] [Related]

  • 15. Increases of substance P-like immunoreactivity within striatal-nigral structures after subacute methamphetamine treatment.
    Ritter JK, Schmidt CJ, Gibb JW, Hanson GR.
    J Pharmacol Exp Ther; 1984 May 01; 229(2):487-92. PubMed ID: 6201607
    [Abstract] [Full Text] [Related]

  • 16. Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system.
    Humpel C, Knaus GA, Auer B, Knaus HG, Haring C, Theodorsson E, Saria A.
    Synapse; 1990 May 01; 6(1):1-9. PubMed ID: 1697986
    [Abstract] [Full Text] [Related]

  • 17. Depletion in substance P- and neurokinin A-like immunoreactivity in substantia nigra after ibotenate-induced lesions of striatum.
    Arai H, Sirinathsinghji DJ, Emson PC.
    Neurosci Res; 1987 Dec 01; 5(2):167-71. PubMed ID: 2448711
    [Abstract] [Full Text] [Related]

  • 18. Neuroleptic treatment induces region-specific changes in levels of neurokinin A and substance P in rat brain.
    Lindefors N, Brodin E, Ungerstedt U.
    Neuropeptides; 1986 Apr 01; 7(3):265-80. PubMed ID: 2423911
    [Abstract] [Full Text] [Related]

  • 19. Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms.
    Reid MS, Herrera-Marschitz M, Hökfelt T, Lindefors N, Persson H, Ungerstedt U.
    Exp Brain Res; 1990 Apr 01; 82(2):293-303. PubMed ID: 1704847
    [Abstract] [Full Text] [Related]

  • 20. Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons.
    Bannon MJ, Lee JM, Giraud P, Young A, Affolter HU, Bonner TI.
    J Biol Chem; 1986 May 25; 261(15):6640-2. PubMed ID: 2422168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.